Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
作者:
作者单位:
Department of Dermatology, Peking University First Hospital, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
[1]
Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China
[2]
Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
[3]
Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China
[4]
Department of Dermatology, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China
[5]
Pfizer S.A. de C.V., Mexico City, Mexico
[6]
Pfizer Inc., New York, NY, USA
[7]
Pfizer Investment Co., Ltd, Beijing 100010, China
[8]
Pfizer (China) R amp;D Co., Ltd, Shanghai 201200, China
[9]
Pfizer PBG, Shanghai 200041, China
[10]
期刊:
《中华医学杂志英文版》2024年137卷16期 1991-1992页
SCIMEDLINEISTICCSCDBP
栏目名称:
Correspondence
DOI:
10.1097/CM9.0000000000003159
发布时间:
2024-09-10
- 浏览:0
- 被引:0
- 下载:0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文